Merck & Company Company Profile (NYSE:MRK)

About Merck & Company

Merck & Company logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: MRK
  • CUSIP: 58933Y10
Key Metrics:
  • Previous Close: $65.39
  • 50 Day Moving Average: $61.60
  • 200 Day Moving Average: $61.72
  • 52-Week Range: $2,757,137,000.00 - $49.24
  • Trailing P/E Ratio: 32.05
  • Foreward P/E Ratio: 15.61
  • P/E Growth: 2.70
  • Market Cap: $180.29B
  • Outstanding Shares: 2,757,137,000
  • Beta: 0.79
  • Net Margins: 14.30%
  • Return on Equity: 24.08%
  • Return on Assets: 10.77%
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 1.89%
  • Quick Ratio: 1.56%
Additional Links:
Companies Related to Merck & Company:

Analyst Ratings

Consensus Ratings for Merck & Company (NYSE:MRK) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.61)
Consensus Price Target: $67.40 (3.07% upside)

Analysts' Ratings History for Merck & Company (NYSE:MRK)
DateFirmActionRatingPrice TargetDetails
2/15/2017BMO Capital MarketsLower Price TargetOutperform$72.00 -> $70.00View Rating Details
1/13/2017Bryan, Garnier & CoInitiated CoverageBuyView Rating Details
1/12/2017Jefferies Group LLCReiterated RatingUnderperform$48.00View Rating Details
1/12/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$72.00View Rating Details
1/12/2017Morgan StanleyUpgradeEqual Weight -> Overweight$65.00 -> $71.00View Rating Details
1/12/2017GuggenheimUpgradeNeutral -> Buy$61.63 -> $70.00View Rating Details
1/11/2017J P Morgan Chase & CoReiterated RatingBuyView Rating Details
10/27/2016ArgusReiterated RatingBuy$65.00 -> $80.00View Rating Details
10/13/2016Bank of America CorpUpgradeNeutral -> Buy$57.00 -> $70.00View Rating Details
10/12/2016Leerink SwannReiterated RatingMarket Perform$65.00View Rating Details
10/12/2016Barclays PLCReiterated RatingOverweightView Rating Details
9/11/2016Berenberg BankReiterated RatingHold$62.00View Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingOutperform$66.00 -> $74.00View Rating Details
8/10/2016Citigroup Inc.Reiterated RatingNeutral$65.00View Rating Details
8/8/2016Deutsche Bank AGBoost Price TargetHold$58.00 -> $59.00View Rating Details
8/7/2016Credit Suisse GroupUpgradeNeutral -> Outperform$62.00 -> $73.00View Rating Details
6/8/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$60.00View Rating Details
4/6/2016Societe GeneraleInitiated CoverageBuyView Rating Details
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00View Rating Details
2/3/2016Cowen and CompanyReiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutralView Rating Details
(Data available from 2/19/2015 forward)


Earnings History for Merck & Company (NYSE:MRK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/2/2017Q416$0.89$0.89$10.22 billion$10.10 billionViewListenView Earnings Details
10/25/2016Q316$0.99$1.07$10.17 billion$10.50 billionViewListenView Earnings Details
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.86$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.80$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merck & Company (NYSE:MRK)
Current Year EPS Consensus Estimate: $3.82 EPS
Next Year EPS Consensus Estimate: $4.19 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.82$0.87$0.84
Q2 20163$0.92$0.92$0.92
Q3 20163$0.97$0.99$0.98
Q4 20163$0.89$0.93$0.90
Q1 20171$0.91$0.91$0.91
Q2 20171$0.93$0.93$0.93
Q3 20171$1.00$1.00$1.00
Q4 20171$1.02$1.02$1.02
(Data provided by Zacks Investment Research)


Current Dividend Information for Merck & Company (NYSE:MRK)
Annual Dividend:$1.88
Dividend Yield:2.88%
Dividend Growth:2.30% (3 Year Average)
Payout Ratio:92.61% (Based on Trailing 12 Months of Earnings)
49.21% (Based on Current Year Consensus EPS Estimate)
44.87% (Based on Next Year Consensus EPS Estimate)
Track Record:5 Years of Consecutive Dividend Growth

Dividend History for Merck & Company (NYSE:MRK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Merck & Company (NYSE:MRK)
Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 74.10%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/8/2017Patricia F RussoDirectorSell5,000$64.42$322,100.00View SEC Filing  
2/6/2017Wendell P WeeksDirectorSell5,000$64.51$322,550.00View SEC Filing  
2/3/2017Michael J HolstonEVPSell91,959$63.96$5,881,697.64View SEC Filing  
2/3/2017Thomas R CechDirectorSell5,000$63.42$317,100.00View SEC Filing  
11/10/2016Kenneth C FrazierChairmanSell140,000$65.03$9,104,200.00View SEC Filing  
11/7/2016Julie L GerberdingEVPSell85,523$60.02$5,133,090.46View SEC Filing  
11/2/2016Rochelle B LazarusDirectorSell20,000$59.06$1,181,200.00View SEC Filing  
10/3/2016Weir Mirian M GraddickInsiderSell40,800$62.07$2,532,456.00View SEC Filing  
9/1/2016Adam H SchechterEVPSell39,200$62.61$2,454,312.00View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000$63.03$189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000$61.81$24,229,520.00View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000$58.00$3,480,000.00View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000$57.99$2,609,550.00View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000$57.69$2,884,500.00View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000$57.49$1,724,700.00View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877$54.79$2,184,860.83View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040$56.11$7,352,654.40View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000$55.53$277,650.00View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313$55.08$2,055,200.04View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666$54.69$1,020,843.54View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000$54.85$274,250.00View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634$60.44$642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368$60.99$2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064$60.20$3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902$59.82$9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624$59.84$5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164$58.67$302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864$58.56$7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000$58.76$293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200$62.48$4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840$62.47$552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846$60.00$590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000$62.00$3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000$59.63$596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000$59.13$295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000$57.98$579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895$59.73$591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814$60.48$593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000$59.70$1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058$57.00$573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669$56.64$1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987$58.03$579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047$59.16$10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290$58.26$4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985$58.06$579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527$55.91$588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047$57.24$575,090.28View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225$56.43$8,195,046.75View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990$55.47$332,265.30View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870$55.04$2,414,604.80View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000$55.61$1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000$55.70$557,000.00View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520$54.52$2,263,670.40View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000$54.44$272,200.00View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000$54.68$2,734,000.00View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638$48.55$2,458,474.90View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208$46.66$1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404$46.15$249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324$44.26$2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Merck & Company (NYSE:MRK)
News IconChecking Out the Technicals for Merck & Co., Inc. (MRK) - The USA Commerce (NYSE:MRK) - February 17 at 4:27 PM
News IconTaking a Fresh Look at Merck & Co., Inc. (MRK) - StockNewsJournal (NYSE:MRK) - February 17 at 4:27 PM logoMerck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market (NYSE:MRK) - February 17 at 4:27 PM
News IconMerck & Company, Inc. (MRK) Shares Bought by Quantitative Systematic Strategies LLC (NYSE:MRK) - February 16 at 6:15 PM logoFossil and AIG slump, Procter & Gamble and Fortress jump (NYSE:MRK) - February 16 at 6:15 PM logoMerck’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions (NYSE:MRK) - February 16 at 6:15 PM logoMerck HIV Drug Doravirine Reports Positive Results (NYSE:MRK) - February 16 at 6:15 PM logoAfter-hours buzz: ANET, TRUE, MRK & more (NYSE:MRK) - February 16 at 6:15 PM
News IconPharma giant Merck is stopping a key Alzheimer's trial because there's 'virtually no chance of finding a positive clinical effect' (NYSE:MRK) - February 15 at 1:15 AM
News IconMerck & Co., Inc. (MRK), Bristol-Myers Squibb Company (BMY) (NYSE:MRK) - February 15 at 1:15 AM
News IconMerck & Company, Inc. (MRK) Shares Sold by Sawtooth Solutions LLC (NYSE:MRK) - February 15 at 1:15 AM logo4:06 pm Merck announces its Phase 3 trial of doravirine (MK-1439) met its primary efficacy endpoint of the proportion of participants achieving levels of HIV-1RNA less than 50 copies/mL after 48 weeks of treatment (NYSE:MRK) - February 15 at 1:15 AM logoMerck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack of Efficacy (NYSE:MRK) - February 15 at 1:15 AM logoMerck shares slip after hours as Alzheimer's study halted (NYSE:MRK) - February 15 at 1:15 AM logoMerck stops trial of Alzheimer's drug (NYSE:MRK) - February 15 at 1:15 AM logoMerck Alzheimer's Drug Study Halted Early for Futility (NYSE:MRK) - February 15 at 1:15 AM logoMerck Alzheimer's drug fails in 1 study; another continues (NYSE:MRK) - February 15 at 1:15 AM logoUPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails - Nasdaq (NYSE:MRK) - February 14 at 8:15 PM
News IconMerck & Company, Inc. (NYSE:MRK) Projected to Achieve EPS Of $0.82 - Stock Observer (NYSE:MRK) - February 14 at 8:15 PM
News IconBrokerage Firms Weigh in on Merck & Company, Inc. (NYSE:MRK) - Rockville Register (NYSE:MRK) - February 14 at 8:15 PM
News IconHalliburton Company (HAL), Merck & Co., Inc. (MRK) Stock Eyes ... - The USA Commerce (NYSE:MRK) - February 14 at 8:15 PM
News IconTaking a Look at the Data Behind Merck & Co., Inc. (MRK) - StockNewsJournal (NYSE:MRK) - February 14 at 8:15 PM
News IconThe Technical Case for and Against Merck & Co., Inc. (MRK) - The USA Commerce (NYSE:MRK) - February 13 at 7:48 PM
News IconAnalyst's Predictions on Exxon Mobil Corporation (XOM), Merck & Co., Inc. (MRK) - StockNewsJournal (NYSE:MRK) - February 13 at 7:48 PM logoThe Zacks Analyst Blog Highlights: Coca-Cola, Walt Disney, Visa, Boeing and Merck (NYSE:MRK) - February 13 at 10:10 AM
News IconAnalysts Near-Term outlook: Merck & Co., Inc. (MRK), Hewlett ... - The USA Commerce (NYSE:MRK) - February 11 at 12:33 AM
News IconDrilling Down Into Merck & Co., Inc. (MRK) - StockNewsJournal (NYSE:MRK) - February 11 at 12:33 AM
News IconToday Analysts Focus on Merck & Co., Inc. (MRK), Texas Instruments Incorporated (TXN) - StockNewsJournal (NYSE:MRK) - February 11 at 12:33 AM logoMerck & Co., Inc. (NYSE:MRK) HPV Vaccine Gardasil Sales Impress, But For How Long? - Market Exclusive (NYSE:MRK) - February 11 at 12:33 AM
News IconDigging Up the Facts on Merck & Co., Inc. (MRK) - StockNewsJournal (NYSE:MRK) - February 11 at 12:33 AM logoMerck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care (NYSE:MRK) - February 9 at 7:41 PM logo[$$] Bristol-Myers Squibb Stock in Bargain Bin (NYSE:MRK) - February 9 at 7:40 PM logoGilead Hepatitis C Meltdown Raises Troubling Question: Is Curing Disease Bad for Business? (NYSE:MRK) - February 8 at 7:32 PM logoMerck's HPV Vaccine Gardasil May Hit Roadblock (NYSE:MRK) - February 8 at 7:32 PM
News IconThe TNB Financial Increases Stake in Merck & Company, Inc. (MRK) (NYSE:MRK) - February 8 at 6:00 AM
News IconMerck & Company, Inc. (NYSE:MRK) Stock Price Target Given At $68.928 - Transcript Daily (NYSE:MRK) - February 8 at 12:59 AM
News IconMerck & Company, Inc. (NYSE:MRK) Projected EPS At $0.82 - Stock Observer (NYSE:MRK) - February 8 at 12:59 AM
News IconMerck & Co., Inc. (MRK) : Checking the Chart - The USA Commerce (NYSE:MRK) - February 8 at 12:59 AM logoThe FDA Accepts Keytruda From Merck & Co., Inc. (MRK) For ... - Insider Monkey (blog) (NYSE:MRK) - February 8 at 12:59 AM
News IconMerck & Co., Inc. (NYSE:MRK), Wal-Mart Stores Inc. (NYSE:WMT) (NYSE:MRK) - February 7 at 7:58 PM
News IconWendell P. Weeks Sells 5000 Shares of Merck & Company, Inc. (MRK) Stock (NYSE:MRK) - February 7 at 7:58 PM logoMerck & Co., Inc. :MRK-US: Earnings Analysis: 2016 By the Numbers : February 7, 2017 (NYSE:MRK) - February 7 at 7:58 PM logoStreamlined FDA Approval Process Would Boost Drug Makers (NYSE:MRK) - February 7 at 7:58 PM
News IconBetter Buy: Merck & Co. Inc. vs. GlaxoSmithKline - Fox Business (NYSE:MRK) - February 7 at 8:16 AM logoBetter Buy: Merck & Co. Inc. vs. GlaxoSmithKline (NYSE:MRK) - February 7 at 8:16 AM
News IconToday's Brokerage Rating: HP Inc. (HPQ), Merck & Co., Inc. (MRK) - StockNewsJournal (NYSE:MRK) - February 6 at 11:45 PM
News IconSphera Funds Management LTD Position in Merck & Co INC (MRK) Has Raised by $12.40 Million as Stock Value Rose (NYSE:MRK) - February 6 at 6:44 PM logoMerck & Co., Inc. :MRK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017 (NYSE:MRK) - February 6 at 6:43 PM logoAgilent (A) Announces Expanded Use of Diagnostic Assay (revised) (NYSE:MRK) - February 6 at 6:43 PM
News IconNotable Earnings: Merck & Co., Inc. (NYSE:MRK) - Post Registrar (NYSE:MRK) - February 6 at 9:47 AM


What is Merck & Company's stock symbol?

Merck & Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Company pay dividends? What is the dividend yield for Merck & Company?

Merck & Company announced a quarterly dividend on Tuesday, November 22nd. Stockholders of record on Thursday, December 15th will be paid a dividend of $0.47 per share on Monday, January 9th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.88%. The ex-dividend date of this dividend is Tuesday, December 13th. This is an increase from Merck & Company's previous quarterly dividend of $0.46.

Where is Merck & Company's stock going? Where will Merck & Company's stock price be in 2017?

18 brokerages have issued 1-year price objectives for Merck & Company's shares. Their predictions range from $48.00 to $80.00. On average, they anticipate Merck & Company's share price to reach $67.40 in the next year.

When will Merck & Company announce their earnings?

Merck & Company is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.

What are analysts saying about Merck & Company stock?

Here are some recent quotes from research analysts about Merck & Company stock:

  • BMO Capital Markets analysts commented, "Although expectations for EPOCH were low, we were looking for an efficacy signal in mild patients, which would have increased expectations for the APECS study. Merck's press release does not provide details regarding subgroup analysis in mild patients; however, the language suggests little to no efficacy. This lowers our probability of success for APECS from 50% to 25%, Verubecestat risk-adjusted sales from ~$5Bn in 2026 to ~$2.5Bn, and our valuation from $72 to $70. However, investors should not give up on Verubecestat; APECS has a higher chance of success." (2/15/2017)
  • Jefferies Group LLC analysts commented, "Our Underperform rating is predicated on under-appreciated margin pressure in the base business as well as over-optimistic expectations for Keytruda." (1/12/2017)

  • According to Zacks Investment Research, "We are positive on the company’s efforts to expand its pipeline and focus on core areas of expertise. Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products, especially Keytruda should contribute meaningfully to the top line. The latest FDA approval of Keytruda for the first line treatment of metastatic lung cancer should sharply improve the drug’s sales. Merck will continue to focus on cost-cutting initiatives to drive the bottom line. The company has also been pursuing acquisitions and business development deals to boost its pipeline. Merck’s shares surpassed that of large-cap pharma industry this year. However, increased competition as well as generic challenges will continue to pressurize the top line. Nasonex and Cubicin lost patent exclusivity in 2016 which is hurting sales." (12/7/2016)

Who owns Merck & Company stock?

Merck & Company's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (1.04%), Barrow Hanley Mewhinney & Strauss LLC (0.64%), FMR LLC (0.49%), Federated Investors Inc. PA (0.41%), Dimensional Fund Advisors LP (0.24%) and AQR Capital Management LLC (0.24%). Company insiders that own Merck & Company stock include Adam H Schechter, Adele D Ambrose, Bruce N Kuhlik, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Peter C Wendell, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks.

Who sold Merck & Company stock? Who is selling Merck & Company stock?

Merck & Company's stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Highland Capital Management LP, Barrow Hanley Mewhinney & Strauss LLC, Tudor Investment Corp Et Al, NN Investment Partners Holdings N.V., Thornburg Investment Management Inc., Menora Mivtachim Holdings LTD. and Cadinha & Co. LLC. Company insiders that have sold Merck & Company stock in the last year include Adam H Schechter, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks.

Who bought Merck & Company stock? Who is buying Merck & Company stock?

Merck & Company's stock was bought by a variety of institutional investors in the last quarter, including Asset Management One Co. Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Russell Investments Group Ltd., AQR Capital Management LLC, Coho Partners Ltd., Congress Asset Management Co. MA, Radnor Capital Management LLC and Orbimed Advisors LLC.

How do I buy Merck & Company stock?

Shares of Merck & Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merck & Company stock cost?

One share of Merck & Company stock can currently be purchased for approximately $65.39.

Merck & Company (NYSE:MRK) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Merck & Company (NYSE:MRK)

Earnings History Chart

Earnings by Quarter for Merck & Company (NYSE:MRK)

Dividend History Chart

Dividend Payments by Quarter for Merck & Company (NYSE:MRK)

Last Updated on 2/19/2017 by Staff